CCR1 and Marchiafava-Bignami disease: Although upregulation of CCL3 was not a unifying molecular abnormality, patients who over-expressed CCL3 gene had abundantly high expression values underlining that CCL3 inhibition with CCR1/5 antagonists could be a potential therapeutic approach for patients whose disease complications (MBD and anemia) are driven by CCL3 (Supplementary Figure 4).